The human epidermal growth factor receptor (HER) family has four receptors: HER-1(EGFR), HER-2, HER-3 and HER-4. These receptors and their associated signaling pathways have been the focus of research and development of targeted therapies. Biologics, such as erlotinib, lapatinib, and trastuzumab, were developed as a result of this research. Many of these targeted therapies use diagnostic tests to identify the best patients for the treatment.
Monogram’s VeraTag® is a proximity-based technology platform designed to detect and quantify proteins and protein-protein complexes, including homodimers and heterodimers of the HER family of cell-surface receptors.